Recursion Pharmaceuticals Inc Class A RXRX

Morningstar Rating
MX$80.98 +10.88 (15.52%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RXRX is trading at a LOCK|#m<gT premium.
Price
MX$81.27
Fair Value
LOCK|H.@?F?tC@<
Uncertainty
LOCK|d< GHdh
1-Star Price
LOCK|P.%xG&C?
5-Star Price
LOCK|.j&?Hr
Economic Moat
LOCK|%K
Capital Allocation
—

Trading Information

Previous Close Price
MX$70.10
Day Range
MX$76.50–81.27
52-Week Range
MX$49.00–121.50
Bid/Ask
MX$76.81 / MX$81.78
Shares Outstanding
536.27M
Market Cap
€43.43B
Volume/Avg
1,362 / 2,846

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
42.36
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
600

Valuation

Metric
RXRX
Price/Earnings (Normalized)
—
Price/Book Value
2.70
Price/Sales
42.36
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
RXRX
Quick Ratio
4.67
Current Ratio
5.03
Interest Coverage
−368.02
Quick Ratio
RXRX

Profitability

Metric
RXRX
Return on Assets (Normalized)
−31.88%
Return on Equity (Normalized)
−42.58%
Return on Invested Capital (Normalized)
−41.51%
Return on Assets
RXRX

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|Tvg?l&LOCK|DNrT$129B
Moderna Inc
MRNA
LOCK|f$mjCtxLOCK|^J$90B
Regeneron Pharmaceuticals Inc
REGN
LOCK|&lFXn&LOCK|h>T@M$77B
argenx SE ADR
ARGX
LOCK|?Dh#%MLOCK|$H$51B
BeOne Medicines Ltd ADR
ONC
LOCK|Ks<fW<&LOCK|nhp$41B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|V?<CyMbLOCK|%>#Q$31B
Royalty Pharma PLC Class A
RPRX
LOCK|pR$wR<%!LOCK|p&f<<$25B
BioNTech SE ADR
BNTX
LOCK|&@%>V%%LOCK|q#P$24B
Incyte Corp
INCY
LOCK|<ZcWyzNLOCK|$w$23B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|D!$vlcLOCK|qQ$14B

Sponsor Center